天智航领跑骨科手术机器人赛道 2025年营收预增最高达67.75%

Core Viewpoint - The surgical robot industry is experiencing accelerated commercialization driven by both policy support and increasing demand [1][2] Group 1: Company Performance - Tianzhihang, known as the "first stock of surgical robots," forecasts a revenue of 270 million to 300 million yuan for 2025, representing a growth of 50.97% to 67.75% compared to the previous year [1] - The company expects a net loss attributable to shareholders of 165 million to 198 million yuan, which is an increase in losses compared to the previous year [1] - The significant revenue growth is attributed to a recovering market environment and increased sales and technical service income [1] Group 2: Market Dynamics - The Tianji orthopedic surgical robot is projected to perform over 49,000 surgeries in 2025, continuing growth from 39,000 surgeries in 2024, with a cumulative total exceeding 150,000 surgeries [1] - The acceptance of surgical robots in the industry is increasing due to advancements by leading manufacturers in technology, service, product maturity, and business models [2] - The orthopedic surgical robot segment is recognized as one of the more mature areas within the surgical robot market, maintaining a leading position in commercialization [2] Group 3: Industry Trends - The domestic market for orthopedic surgical robots is expected to see over 100 units awarded in procurement by 2025, with a market growth rate of approximately 35% year-on-year [2] - Tianzhihang holds a leading market share of over 40% in the domestic orthopedic surgical robot market [2] - Recent policy changes, including a unified pricing framework for robotic surgeries, are anticipated to provide systemic support for the entire surgical robot industry, with orthopedic surgical robots likely to be the primary beneficiaries due to strong clinical demand and a large patient base [2]